Effects of the novel antimigraine agent, frovatriptan, on coronary and cardiac function in dogs

Journal of Cardiovascular Pharmacology

Volumn 32, Issue 6, 1998, Pages 995-1000

  Parsons, Andrew A ^a   Valocik, Richard ^b   Koster, Paul ^b   Raval, Pravin ^a   Gagnon, Robert ^b   Tilford, Nick ^a,c   Feuerstein, Giora ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Dept of Cardiovascular Pharmacology SmithKline Beecham ^*  (United States)

^c Pharmagene Laboratories   (United Kingdom)

Author keywords

Coronary artery function; Frovatriptan; Sumatriptan

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ANTIMIGRAINE AGENT; FROVATRIPTAN; SUMATRIPTAN SUCCINATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY BLOOD FLOW; CORONARY VASCULAR RESISTANCE; DOSE RESPONSE; HEART HEMODYNAMICS; HEART INFARCTION; INTRACORONARY INFUSION; INTRAVENOUS DRUG ADMINISTRATION; MIGRAINE; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE CONTRACTION;

EID: 0031674712     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199812000-00018     Document Type: Article

References (30)

1. 1D receptors. Br J Pharmacol 1996;119:110P.
2. 1B/1D agonist for the treatment of acute migraine. Cephalalgia 1997;17:418.
3. 1B/1D receptor agonist, SB-209509 (VML 251), and sumatriptan in dogs. J Cardiovasc Pharmacol 1997;30:136-41.
4. 1B/1D receptor ligand, frovatriptan in human isolated basilar and coronary arteries. J Cardiovasc Pharmacol 1998;32:220-4.
5. MassenvandenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Current and future anti-migraine drugs in the human isolated coronary artery. Br J Pharmacol 1997;12:68P.
6. 2 receptor activation. Eur J Pharmacol 1989;161:91-4.
7. Ferro A, Longmore J, Hill RG, Brown MJ. A comparison of the contractile effects of 5-hydroxytryptamine, sumatriptan and MK-462 on human coronary artery in vitro. Br J Clin Pharmacol 1995;40:245-51.
8. 1D receptor agonists and human coronary artery reactivity in vitro: crossover comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519. Br J Clin Pharmacol 1996;42:431-41.
9. Connor HE, Feniuk W, North PC, Oxford AW, Saynor DA, Humphrey PPA. Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia 1997;17:145-52.
10. 2 receptors in serotonin-induced contraction of human isolated coronary arteries Circulation 1994;190:1141-53.
11. Bax WA, Renzenbrink GJ, vanHeuven-Nolsen D, Thijssem EJM, Bos E, Saxena PR. 5-HT receptors mediating contractions of the isolated human coronary artery. Eur J Pharmacol 1993;239:203-10.
12. Chester AH, Martin GR, Bodelsson M, et al. 5-Hydroxytryptamine receptor profile in healthy and diseased human epicardial coronary arteries. Cardiovasc Res 1990;24:932-7.
13. 1 receptor agonist on haemodynamics and the coronary circulation. Br J Clin Pharmacol 1992;34:541-6.
14. 1 agonist on systemic, pulmonary and coronary circulations. Circulation 1993;34:541-6.
15. 2, positron emission tomography. Neurology 1997;48:1542-50.
16. McFadden EP, Clarke JG, Davies GJ, Kaski JC, Haider AW, Maseri A. Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. N Engl J Med 1991;324:648-54.
17. Golino P, Piscione F, Willerson JT, et al. Divergent effects of serotonin on coronary-artery diameter and blood flow in patients with coronary atherosclerosis and control patients. N Engl J Med 1991;324:641-8.
18. 1-like receptors. Naunyn Schmiedebergs Arch Pharmacol 1992;346:592-6.
19. Burmeister WE, Reynold RD, Lee RJ. Limitation of myocardial infarct size by atenolol, nadolol, and propranolol in dogs. Eur J Pharmacol 1981;75:7-10.
20. Endo T, Soato N, Hayakawa H, Maroko PR. Reduction in myocardial hemorrhage and the extent of necrosis by gallopamil (D600) in dogs with coronary artery reperfusion. J Cardiovasc Pharmacol 1991;18:739-45.
21. Colatsky TJ. Model of myocardial ischemia and reperfusion injury: role of inflammatory mediators in determining infarct size. In: Liss AR, ed. Pharmacological methods in control of inflammation. New York: John Wiley & Sons, 1989:283-320.
22. Cushing DJ, Cohen ML. Serotonin-induced relaxation in canine coronary artery smooth muscle. J Pharmacol Exp Ther 1992;263:123-9.
23. 7 receptor ligand blocks serotonin-induced relaxation in canine coronary artery. J Pharmacol Exp Ther 1996;277:1560-6.
24. Massenvanden Brink A, Bax WA, Ferrari MD, Zijlstra FJ, Bos E, Saxena PR. Augmented contraction of the human isolated coronary artery by sumatriptan: a possible role for endogenous thromboxane. Br J Pharmacol 1990;119:855-62.
25. Chester AH, Allen SP, Tadjkarimi S, Yacoub MH. Interaction between thromboxane A2 and 5-hydroxytryptamine receptor subtypes in human coronary arteries. Circulation 1993;87:874-80.
26. Kemp BK, Cocks TM. Effects of U46619 on contractions to 5-HT, sumatriptan and methysergide in canine coronary artery and saphenous vein. Br J Pharmacol 1995;116:2183-90.
27. Ellwood AJ, Curtis MJ. Mechanism of actions of sumatriptan on coronary flow before and after endothelial dysfunction in guinea-pig isolated heart. Br J Pharmacol 1997;120:1039-48.
28. 1-receptor agonist. Br J Clin Pharmacol 1997;43:327-8.
29. 1-like receptor activation. Br J Pharmacol 1995;116:2207-12.
30. 1-like receptors in myocardial infarction and blood flow in a beagle dog model. Br J Pharmacol 1988;95:493P.